Datapoint: Merck and Bayer’s Verquvo Scores FDA Approval

The FDA on Tuesday approved Bayer and Merck & Co.’s blockbuster hopeful Verquvo for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). In the HFrEF market basket, the drug will have to face off against Novartis’ first-in-class Entresto, which currently holds preferred status for 50% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/20/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today